Conmed Corp CNMD
We take great care to ensure that the data presented and summarized in this overview for CONMED Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CNMD
View all-
Black Rock Inc. New York, NY5.12MShares$387 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.46MShares$262 Million0.01% of portfolio
-
Earnest Partners LLC Atlanta, GA2.37MShares$179 Million0.9% of portfolio
-
Capital Research Global Investors Los Angeles, CA1.46MShares$111 Million0.03% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.3MShares$98.6 Million0.62% of portfolio
-
State Street Corp Boston, MA1.22MShares$92 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC1.02MShares$76.8 Million0.01% of portfolio
-
Westwood Holdings Group Inc Dallas, TX839KShares$63.5 Million0.53% of portfolio
-
Macquarie Group LTD Australia, C3829KShares$62.7 Million0.08% of portfolio
-
Dimensional Fund Advisors LP Austin, TX771KShares$58.3 Million0.02% of portfolio
Latest Institutional Activity in CNMD
Top Purchases
Top Sells
About CNMD
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Insider Transactions at CNMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 13
2024
|
David M Bronson Director |
BUY
Open market or private purchase
|
Direct |
1,350
+7.58%
|
$97,200
$72.09 P/Share
|
|
May 08
2024
|
Barbara J Schwarzentraub Director |
BUY
Open market or private purchase
|
Indirect |
1,442
+50.0%
|
$99,498
$69.26 P/Share
|
|
May 06
2024
|
Martha Goldberg Aronson Director |
BUY
Open market or private purchase
|
Indirect |
2,000
+50.0%
|
$140,000
$70.98 P/Share
|
|
Apr 30
2024
|
Pat Beyer Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+21.73%
|
$204,000
$68.3 P/Share
|
|
Mar 28
2024
|
Todd W Garner Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
227
+50.0%
|
$17,252
$76.08 P/Share
|
|
Mar 28
2024
|
Heather L Cohen EVP & Chief HR & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
227
+0.63%
|
$17,252
$76.08 P/Share
|
|
Mar 08
2024
|
Heather L Cohen EVP & Chief HR & Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
46,105
-39.57%
|
$3,918,925
$85.32 P/Share
|
|
Mar 08
2024
|
Heather L Cohen EVP & Chief HR & Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
52,500
+31.07%
|
$3,622,500
$69.36 P/Share
|
|
Mar 07
2024
|
Brent Lalomia Vice President QA and RA |
SELL
Payment of exercise price or tax liability
|
Direct |
26
-2.65%
|
$2,210
$85.0 P/Share
|
|
Mar 07
2024
|
Brent Lalomia Vice President QA and RA |
BUY
Exercise of conversion of derivative security
|
Direct |
75
+7.09%
|
-
|
|
Dec 04
2023
|
Stanley W Peters Iii President AS and AET |
SELL
Open market or private sale
|
Direct |
2,300
-97.33%
|
$250,700
$109.93 P/Share
|
|
Dec 04
2023
|
Stanley W Peters Iii President AS and AET |
BUY
Exercise of conversion of derivative security
|
Direct |
2,300
+49.32%
|
$94,300
$41.93 P/Share
|
|
Nov 07
2023
|
Stanley W Peters Iii President AS and AET |
SELL
Open market or private sale
|
Direct |
1,200
-95.01%
|
$122,400
$102.39 P/Share
|
|
Nov 07
2023
|
Stanley W Peters Iii President AS and AET |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+48.72%
|
$49,200
$41.93 P/Share
|
|
Sep 13
2023
|
Stanley W Peters Iii President AS and AET |
SELL
Open market or private sale
|
Direct |
2,000
-96.95%
|
$214,000
$107.31 P/Share
|
|
Sep 13
2023
|
Stanley W Peters Iii President AS and AET |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+49.22%
|
$82,000
$41.93 P/Share
|
|
Aug 16
2023
|
Todd W Garner Executive Vice President & CFO |
SELL
Open market or private sale
|
Direct |
1,355
-100.0%
|
$151,760
$112.0 P/Share
|
|
Jun 30
2023
|
Heather L Cohen EVP & Chief HR & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16
+0.05%
|
$2,064
$129.1 P/Share
|
|
Jun 17
2023
|
Brent Lalomia Vice President QA and RA |
SELL
Payment of exercise price or tax liability
|
Direct |
71
-7.25%
|
$9,585
$135.64 P/Share
|
|
Jun 17
2023
|
Brent Lalomia Vice President QA and RA |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+20.34%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 72.2K shares |
|---|---|
| Grant, award, or other acquisition | 470 shares |
| Open market or private purchase | 7.79K shares |
| Payment of exercise price or tax liability | 48.9K shares |
|---|---|
| Open market or private sale | 15.4K shares |